Thu, Feb 1, 2024 12:57 PM
Ajanta Pharma Q3 net profit jumps 56% YoY to Rs 210 crore
A Flip by Shubhangi Gupta
The Reserve Bank of India's recent regulatory actions on microfinance institutions (MFIs) and non-banking financial companies (NBFCs) aim to address concerns over excessive interest rates and unmanaged growth in unsecured lending, but the measures may be seen as excessive and could have unforeseen consequences.
Open Flip
Sun Pharma's revenue and EBITDA met estimates, but Adj. PAT missed due to higher finance costs and lower other income. Despite this, KR Choksey increases the target price to INR 1,967/share, citing growth potential in the US specialty business and effective cost control measures, maintaining an "ACCUMULATE" rating.
Open Flip
Reported Standalone quarterly numbers for MPS are: Net Sales at Rs 86.68 crore in Sept 2024 up 7.78% from Rs. 80.42 crore in September 2023. Quarterly Net Profit at Rs. 26.92 crore in September 2024 up 11.29% from Rs. 24.19 crore in September 2023. EBITDA stands at Rs. 39.43 crore in September 2024 up 9.83% from Rs. 35.90 crore in September 2023. MPS EPS has increased to Rs. 15.87 in September.
Open Flip
